Pharma

Your Article Summary

See Latest Articles

Afinitor and Sandostatin LAR Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months
Novartis, 06/25/09

New data demonstrate that treatment with Afinitor Tablets in combination with Sandostatin LAR and Afinitor monotherapy may have the potential to control tumor growth in patients with advanced pancreatic neuroendocrine tumors. These results will be presented at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09

Phase III CONFIRM study shows FASLODEX (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
AstraZeneca, 12/11/09

Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09

 See all of Research & Development